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In the last few years it has become apparent that the
skin is a locoregional source for several proopio-
melanocortin-derived peptides including a-melano-
cyte-stimulating hormone, adrenocorticotropin, and
b-endorphin. The enzymes that regulate expression
of these neuropeptides are the prohormone convert-
ases 1 and 2. In this study we demonstrate, by
reverse transcriptase polymerase chain reaction and
Western immunoblotting, that cultured human
dermal ®broblasts express prohormone convertases 1
and 2 as well as 7B2, which is an essential cofactor
for enzymatic activity of prohormone convertase 2.
Immuno¯uorescence studies revealed prohormone
convertase 1 to be mainly expressed in the peri-
nuclear region in vesicular structures resembling the
trans-Golgi network, whereas prohormone convertase
2 was found in the trans-Golgi network as well as in
vesicular structures diffusely distributed in the peri-
pheral cytoplasm. Expression of both enzymes was
also con®rmed in ®broblasts of normal adult human
skin by immunohistochemistry using antibodies
against prohormone convertases 1 and 2 and vimen-
tin. To assess the relevance of prohormone convert-
ase 1 and 2 expression in human dermal ®broblasts,
we studied the expression of proopiomelanocortin
and proopiomelanocortin-derived peptides. Proopio-
melanocortin expression was detected by reverse
transcriptase polymerase chain reaction and Western
immunoblotting. a-Melanocyte-stimulating hor-
mone, adrenocorticotropin, and b-endorphin were
mainly located in vesicular structures as demon-
strated by immuno¯uorescence. Production of these
peptides was con®rmed by radioimmunoassay,
immunoradiometric assay, or enzyme immunoassay.
Among several stimuli tested, interleukin-1 was
found to upregulate production of a-melanocyte-
stimulating hormone in human dermal ®broblasts.
In summary, we have shown that human dermal
®broblasts express the enzymatic machinery for
proopiomelanocortin processing and make proopio-
melanocortin, a-melanocyte-stimulating hormone,
adrenocorticotropin, and b-endorphin. Production
of proopiomelanocortin peptides by human dermal
®broblasts may be relevant for ®broblast functions
such as collagen degradation and/or regulation of
dermal immune responses. Key words: adrenocortico-
tropin/b-endorphin/®broblasts/melanocyte-stimulating hor-
mone/prohormone convertases/proopiomelanocortin. J Invest
Dermatol 117:227-235, 2001
P
roopiomelanocortin (POMC) peptides comprise a
number of bioactive substances that are derived from a
large precursor prohormone of approximately 31 kDa.
Two prohormone convertases, PC1 and PC2, belonging
to an evolutionary conserved family of serine proteinases
of the subtilisin/kexin type, have been found to be associated with
POMC peptide expression (Seidah et al, 1999). Whereas PC1
activity results in adrenocorticotropin (ACTH) and b-lipotropin
formation, PC2 catalyzes the formation of a-melanocyte-stimulat-
ing hormone (a-MSH), b-endorphin (b-ED), and corticotrophin-
like intermediate lobe peptide (Benjannet et al, 1991; Seidah et al,
1999). PC2 activity itself is partly regulated by a chaperone-like
binding protein named 7B2, which facilitates zymogene activation
of the precursor PC2 (Benjannet et al, 1998; Apletalina et al, 2000).
7B2 is also required for development of the full enzymatic activity
of PC2 (Zhu and Lindberg, 1995).
POMC peptides elicit a plethora of biologic effects including
behavioral, cognitive, immunomodulating, antimicrobial, pigment-
ary, nutritional, and thermoregulatory effects (Hadley and Haskell-
Luevano, 1999; Luger et al, 1999b; Cutuli et al, 2000). With regard
to the skin, a-MSH has attained most attraction as it has originally
been characterized as an important regulator of the coat color in
many vertebrate species (Lerner and McGuire, 1961; Thody and
Graham, 1998). In addition, an increasing number of studies
demonstrated that a-MSH exerts potent immunoregulatory effects,
which may be relevant for cutaneous immune responses and
in¯ammation (Slominski et al, 2000). a-MSH suppresses the
production of certain immunoregulatory and proin¯ammatory
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cytokines such as interleukin-1 (IL-1), IL-6, interferon-g, and
tumor necrosis factor a (TNF-a) (Catania and Lipton, 1993; Luger
et al, 1993; 1999a). Expression of the costimulatory molecules
CD86 and CD40 is suppressed by a-MSH (Bhardwaj et al, 1997).
a-MSH induces the production of the cytokine synthesis inhibitory
factor IL-10 in human monocytes (Bhardwaj et al, 1996; Becher
et al, 1999). Depending on the cell type studied, a-MSH can
downregulate lipopolysaccharide- or TNF-a-induced expression
of the vascular cellular adhesion molecule 1 and intercellular
adhesion molecule 1 (Hedley et al, 1998; Morandini et al, 1998;
Kalden et al, 1999) as well as lipopolysaccharide-mediated
activation of the transcription factor NF-kB (Manna and
Aggarwal, 1998; Brzoska et al, 1999; Kalden et al, 1999). These
effects may represent parts of the molecular mechanisms by which
a-MSH suppresses the induction as well as the elicitation phase in a
mouse model of contact hypersensitivity, or by which a-MSH
suppresses the experimentally provoked cutaneous vasculitis
induced by lipopolysaccharide (Grabbe et al, 1996; SunderkoÈtter
et al, 1999).
In contrast to a-MSH, the biologic activities of ACTH and
b-ED in the skin are less de®ned. ACTH, beyond its ability to
induce pigmentation (Wintzen and Gilchrest, 1996; Thody et al,
1998; Hirobe and Abe, 2000), can regulate lipogenesis in murine
adipocytes as the receptor for ACTH has been identi®ed on these
cells (Boston and Cone, 1996; Boston, 1999). Increased plasma
levels of b-ED were found in patients with psoriasis, atopic
dermatitis, and systemic sclerosis, and in individuals exposed to
ultraviolet (UV) light (Levins et al, 1983; Glinski et al, 1994). In situ
expression of b-ED on the protein level was pronounced in
dysplastic nevus, basal cell carcinoma, keratoacanthoma, and
psoriatic skin as demonstrated by immunostaining (Slominski et
al, 1993). Detection of m-opioid receptors in a variety of cutaneous
cell types further suggests an important role of b-ED in skin
physiology and a bidirectional neuroimmuno-dermatologic axis
(Bigliardi et al, 1998; Bigliardi-Qi et al, 2000).
It is established that POMC peptides are widely expressed in
several extraneural tissues including the skin (Thody et al, 1983;
Blalock, 1999; Solomon, 1999). POMC mRNA and various
POMC peptides are present in normal and human diseased skin
(Slominski et al, 1993; Nagahama et al, 1998), and several skin cell
types produce a-MSH and ACTH (Schauer et al, 1994; Slominski
et al, 1996; Wintzen et al, 1996) and b-ED (Levins et al, 1983;
Zanello et al, 1999). With regard to dermal ®broblasts, Teofoli et al
(1997) have recently detected POMC expression on the mRNA
level; however, nothing is known about the enzyme machinery
that generates the mature POMC products a-MSH, ACTH, and
b-ED (Teofoli et al, 1999). In this paper we demonstrate that
human dermal ®broblasts (HDF) in culture and in situ express PC1
and PC2. Moreover, we have examined POMC expression as well
as several stimuli that may regulate POMC peptide production and
secretion.
MATERIALS AND METHODS
Cell culture HDF derived from neonatal foreskin were purchased
from BioWhittaker (Walkersville, MD) and maintained in RPMI 1640
(Biochrom, Berlin, Germany) supplemented with 10% fetal bovine
serum (FBS), 1% glutamine, and 1% penicillin/streptomycin (all from
Biochrom) in a humidi®ed atmosphere of 5% CO2. The cells were used
in passages 3±8 only. Normal human melanocytes (NHM) were
purchased from BioWhittaker and cultured with all supplements
according to the manufacturer.
Preparation of RNA Total RNA was isolated from HDF and NHM
using an SV Total RNA isolation kit from Promega, Madison, WI. To
avoid DNA contamination the extracted RNA was additionally treated
with 10 U RNAse-free DNase I for 1 h at 37°C (Promega).
Reverse transcriptase polymerase chain reaction (RT-PCR) For
RT-PCR, 2 mg of total RNA was reverse transcribed using oligo(dT)
primers and AMV Reverse Transcriptase (Promega). PCR ampli®cation
was performed with REDTaq polymerase (Sigma, Taufkirchen,
Germany) and commercially synthesized speci®c primer pairs (Gibco-
BRL, Gaithersburg, MD) as listed below. The reaction mixture
contained 1 3 REDTaq PCR buffer (10 3 100 mM Tris-HCl, pH 8.3,
500 mM KCl, 11 mM MgCl2, and 0.1% gelatin), 0.05 unit per ml
REDTaq DNA polymerase (both Sigma), 0.2 mM dNTP (each) mixture
(Promega), and 40 pmol of each primer. Nucleotide sequences for PCR
primers and ampli®cation programs were as follows: PC1 was ampli®ed
with the sense primer 5¢-AGCAAACCCAAATCTCACCTG-3¢ and the
antisense primer 5¢-TCTCCACCCCTCTTCTGTCAT-3¢ yielding a
674 bp cDNA by one cycle at 94°C for 10 min, 53°C for 45 s, 72°C
for 1 min, followed by 33 cycles at 94°C for 45 s, 53°C for 45 s, 72°C
for 1 min, and a ®nal cycle at 94°C for 45 s, 53°C for 45 s, 72°C for
10 min; PC2 was ampli®ed with the sense primer 5¢-AACGCA-
ACCAGAAGAGGAGA-3¢ and the antisense primer 5¢-ATGGCCAAC-
TTGGACTGGTA-3¢ yielding a 299 bp cDNA by one cycle at 94°C for
5 min, followed by 38 cycles at 94°C for 30 s, 68°C for 45 s, 72°C for
45 s, and a ®nal cycle at 94°C for 30 s, 68°C for 45 s, 72°C for 10 min;
7B2 was ampli®ed using the sense primer 5¢-CACCAGGCCATG-
AATCTT-3¢ and the antisense primer 5¢-CTGGATCCTTATCCT-
CATCTG-3¢ yielding a 454 bp cDNA by one cycle at 94°C for 10 min,
68°C for 1 min, 72°C for 1 min, followed by 33 cycles at 94°C for 45 s,
68°C for 45 s, 72°C for 1 min, and a ®nal cycle at 94°C for 45 s, 68°C
for 45 s, 72°C for 10 min; POMC was ampli®ed by the primer pairs
previously described by Slominski and a modi®ed protocol with one
cycle at 94°C for 10 min, 68°C for 45 s min, 72°C for 1 min, 33 cycles
at 94°C for 45 s, 68°C for 45 s, 72°C for 1 min, and a ®nal cycle at
94°C for 45 s, 68°C for 45 s, 72°C for 10 min (Slominski et al, 1995).
To exclude that RNA samples were contaminated with genomic DNA,
RNA samples that were not reverse transcribed as well as samples
without cDNA were ampli®ed. PCR products were separated
electrophoretically on 1.5% TAE-agarose gels, stained with ethidium
bromide, and photographed under UV.
Western immunoblot analysis HDF and NHM were scraped into
lysis buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 10% glycerol, 1%
Triton X-100, 1.5 mM MgCl2, 1 mM ethyleneglycol-bis(b-aminoethyl
ether)-N,N,N¢,N¢-tetraacetic acid, 100 mM NaF, 0.01% NaN2)
supplemented with protease inhibitors (10 mg per ml aprotinin, 5 mg per
ml leupeptin, and 1 mM phenylmethylsulfonyl ¯uoride) as described
previously (BoÈhm et al, 1995). Protein concentration was measured by
the modi®ed Bradford assay (Bio-Rad, Richmond, CA). Whole cell
lysates from SK-N-MC cells were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA). Identical amounts of lysate proteins
(usually 30 mg per lane) were separated by 12% or 4%±12% gradient
NuPAGE (Invitrogen, Carlsbad, CA) and electroblotted onto
polyvinylidene di¯uoride membranes (Bio-Rad). Membranes were
blocked overnight with 10% bovine serum albumin (BSA) and
immunoprobed at 4°C overnight with anti-PC1 (Chemicon, Temecula,
CA), anti-PC2 (1:500), or anti-7B2 (1:1000). The last two antibodies
were generous gifts from Dr. N. Seidah, Montreal, Canada. POMC was
detected using an anti-ACTH antibody (Sigma) directed against a
common epitope of both ACTH and POMC (ACTH18-39). Membranes
were incubated for 20 min with a horseradish-peroxidase-conjugated
donkey anti-rabbit IgG antibody (Amersham Life Science, Freiburg,
Germany). Antibody±antigen complexes were visualized by the enhanced
chemiluminescence kit (Amersham Pharmacia Biotech, Uppsala,
Sweden).
Immuno¯uorescence Cells seeded into eight-well tissue chambers
(Laboratory-Tek, Nalge Nunc Int, Naperville, IL) were ®xed and
permeated with methanol for 30 min at ±20°C. Unspeci®c binding was
blocked with 5% donkey serum for 1 h at room temperature. Cells were
then incubated for 2 h at room temperature with anti-PC1 (1:100) and
anti-PC2 (1:200), both from Alexis, San Diego, CA; anti-a-MSH (1:50,
Peninsula, San Carlos, CA) with no crossreactivity against b-MSH, g-
MSH, ACTH, Met-enkephalin, a-, b-, or g-ED; anti-ACTH (1:100,
Sigma) reactive against ACTH 18±39 and ACTH 1±39, but not against
ACTH 1±17 and ACTH 1±10; and anti-b-ED (1:100, DRG, Marburg,
Germany) with no crossreactivity against a-MSH, ACTH, or Met-
enkephalin. After washing, bound antibodies were visualized by
secondary donkey anti-rabbit antibodies conjugated with Texas Red
(1:100, Dianova, Hamburg, Germany). In some experiments, the
secondary antibody was coincubated with ¯uorescein isothiocyanate
(FITC) conjugated wheat germ agglutinin (WGA) 1:250, Sigma. After
three ®nal washes, slides were mounted in Mowiol (Hoechst, Frankfurt,
Germany) and stored at ±20°C until use. For negative controls, whole
rabbit serum was used instead of the primary antibody or the primary
antibody was omitted.
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Confocal laser scanning microscopy Cells were imaged with a
confocal laser scanning microscope (TCS E, Leica, Heidelberg,
Germany). Red and green ¯uorescence were excited with the 568 nm
and 488 nm lines of an air-cooled Ar±Kr laser, and emissions were
measured beyond 590 nm and 510 nm. Data acquisition conditions were
carefully optimized by using 8-fold frame averaging, an oil immersion
objective (1003, NA 1.3; or 403, NA 1.0), and a pinhole size of 2.5
optical units. Under these experimental conditions, lateral and axial
resolutions of 0.27 and 0.49 mm, respectively, are obtained (Kubitscheck
and Peters, 1998). Care was taken to exploit the 8 bit dynamic range of
the instrument fully. Laser power was adjusted such that no signi®cant
photobleaching occurred during the experiments.
Cell treatment HDF were plated at a density of 0.5 3 106 per ml
into 100 mm Petri dishes in complete medium. They were switched to
RPMI 1640 containing 2% FBS 24 h prior to treatment. Phorbol
myristate acetate (PMA, Sigma) or recombinant human IL-1b (Roche
Diagnostics, Mannheim, Germany) were added to a ®nal concentration
of 10 ng per ml each. For UV irradiation cells were exposed to UVA
light at a dose of 15 J per cm2 (Scharffetter et al, 1991; Wlaschek et al,
1994). The source of the UV light was a UVA device Sellasol
(SellasSunlight, Gevelsberg, Germany), which emits most of its energy
within the UVA range (320±400 nm) with an emission peak at 365 nm.
During UV exposure, culture medium was replaced by phosphate-
buffered saline (PBS) and cells were maintained at 37°C in a water bath.
Mock-irradiated cells were subjected to the identical procedure except
irradiation.
Determination of POMC-derived peptides Culture supernatants
and cellular extracts were harvested 24 and 48 h after treatment with the
indicated stimuli. Supernatants were supplemented with protease
inhibitors (10 mg per ml aprotinin, 5 mg per ml leupeptin, 1 mM
phenylmethylsulfonyl ¯uoride), centrifuged at 4500g, and stored at
±80°C until use. Cells were harvested into lysis buffer (for a-MSH and
ACTH) or PBS (for b-ED) supplemented with protease inhibitors as
described above. Supernatants (10 ml) and cellular extracts (1 ml) used
for detection of a-MSH were 45- and 5-fold concentrated using C18
columns (Waters, Milford, MA). For detection of a-MSH a
commercially available radioimmunoassay was used (Euro-Diagnostica,
MalmoÈ, Sweden). The detection limit of this assay was 5 pg per ml with
no crossreactivity against des-amido-a-MSH, ACTH 1±13, ACTH 1±
24, ACTH 1±39, b-MSH, and g-MSH. ACTH was measured by an
immunoradiometric assay from DiaSorin (Stillwater, MN); the sensitivity
was 1.5 pg per ml with crossreactivity of less than 0.1% for ACTH 18±
24, ACTH 1±10, b-ED, a-MSH, and b-MSH. b-ED was measured
using an enzyme immunoassay from Peninsula Laboratories (Belmont,
CA), with a sensitivity of 40 pg per ml and no crossreactivity against
a-MSH, ACTH, g-ED, a-ED, Met-enkephalin, or dynorphin. A
standard curve was constructed for each assay. Experiments were
performed at least three times. Data were analyzed by the unpaired
Student's t test.
Immunohistochemistry Samples of normal adult human skin
(n = 2) derived from patients undergoing routine surgery for therapeutic
or diagnostic reasons were examined. The specimens were ®xed and
processed as described previously (BoÈhm et al, 1999a). For epitope
unmasking sections were microwave treated for 15 min. Sections were
subsequently quenched for endogenous peroxidase by incubating with
1% methanolic hydrogen peroxide for 20 min. After rinsing with PBS,
unspeci®c binding sites were blocked with 2% BSA for 30 min at room
temperature followed by incubation for 24 h with anti-PC1 (1:800) or
anti-PC2 (1:400, both from Chemicon) diluted in 1% BSA. The sections
were ®nally developed by an indirect immunoperoxidase technique using
the following reagents: PBS, peroxidase-conjugated goat antirabbit
antibodies (1:250, Dianova, Hamburg, Germany), 0.01% hydrogen
peroxide, and 3-amino-9-ethylcarbazole as a chromogenic substrate
(Sigma). For negative controls, the primary antibody was omitted. For
double immunostaining a colloidal gold/silver enhancement technique
was combined with the immunoperoxidase technique (Lucocq and
Roth, 1985). Unspeci®c binding sites were blocked as described. Then,
the sections were treated with a monoclonal vimentin antibody (1:200,
Dako, Hamburg, Germany) for 45 min followed by incubation with a
1 nm gold-labeled goat antimouse antibody (1:10, Biotrend, Cologne,
Germany). Bound antibodies were visualized by a commercial silver
enhancement assay (Biotrend). After washing and preincubation with 2%
BSA the slides were further processed with the polyclonal PC1 or PC2
antibodies and indirect immunoperoxidase technique as described above.
Counterstaining was performed with Harris's hematoxylin (Merck,
Darmstadt, Germany).
RESULTS
Expression of PC1, PC2, and 7B2 in HDF in culture As
PC1 and PC2 have been shown to cleave POMC into the
bioactive POMC peptides, we ®rst examined the expression of
PC1, PC2, and 7B2 in HDF. RT-PCR with speci®c primers
against PC1, PC2, and 7B2 produced ampli®cation products of the
same size in HDF and NHM (Fig 1a±c). The latter cell type was
used as a positive control, as cultured NHM have been reported to
express PC1 and PC2 and are capable of producing POMC
peptides in vitro (Peters et al, 2000). All ampli®cation products were
of the expected size. Artifacts due to traces of undigested genomic
DNA were excluded by processing total RNA samples that were
not reverse transcribed or samples without cDNA (Fig 1a±c). To
check if mRNA expression of PC1, PC2, and 7B2 is associated
with protein production, we examined complete cell lysates from
HDF and NHM by Western immunoblotting (Fig 2). The anti-
PC1 antibody detected a double band of 84 and 72 kDa in HDF
representing the low active and very active isoform of the enzyme
(Seidah et al, 1999). The lower band in HDF comigrated with a
72 kDa protein in NHM (Fig 2a). In addition, the anti-PC1
antibody detected one protein of approximately 46 kDa in HDF,
and one of approximately 51 kDa in NHM, probably degradation
Figure 1. Detection of PC1-, PC2-, and 7B2-speci®c transcripts
by RT-PCR in HDF in culture. Total RNA was extracted from
cultured cells, reverse transcribed, and ampli®ed with speci®c primers
against PC1, PC2, and 7B2, followed by 1.5% agarose gel
electrophoresis. (a) Detection of a 674 bp product speci®c for PC1; (b) a
299 bp product speci®c for PC2; and (c) a 454 bp product speci®c for
7B2 in both HDF and NHM (positive control). NC 1, ®rst negative
control (substitution of template with H2O); NC 2, second negative
control (substitution of template with total RNA).
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products of PC1 as the activated isoform has been found to be an
unstable enzyme (Fig 2a) (Zhou and Lindberg, 1994). We were
unable to detect the low active PC1 84 kDa isoform in NHM,
however, as described previously (Peters et al, 2000), possibly due
to differences in the sample preparation and insuf®cient epitope
unmasking under denaturing conditions. The anti-PC2 antibody
detected a 66 kDa protein in both HDF and NHM (Fig 2b).
Western immunoblotting with anti-7B2 antibodies revealed a
single protein of approximately 23 kDa in the range of expected
size (Benjannet et al, 1995; Zhu et al, 1995) (Fig 2c).
Subcellular distribution of PC1 and PC2 in HDF PC1 and
PC2 were found to be distributed in special organelles within
neuroendocrine cells (Vindrola and Lindberg, 1992; Benjannet
et al, 1993). Thus, we next visualized PC1 and PC2 in HDF by
indirect immuno¯uorescence (Fig 3). Almost all cells exhibited
immunostaining in which PC1 appeared to be mainly distributed in
the perinuclear region in reticular and vesicular structures, whereas
PC2 was localized in the juxtanuclear posed region and, to a lesser
degree, in vesicular structures diffusely distributed in the cytoplasm
(Fig 3a, c). To further specify the subcellular localization of PC1
and PC2, ®broblasts were double stained with PC1 or PC2 and
FITC-conjugated WGA. WGA is a lectin-binding protein that has
been demonstrated to bind to the trans-Golgi network (TGN)
(Renau-Piqueras et al, 1997; Minana et al, 1998). As expected,
WGA staining occurred in the perinuclear region and the TGN
(Fig 3b, d). Double immuno¯uorescence revealed colocalization of
WGA staining and PC1 immunoreactivity within these structures
(Fig 3a, b). PC2 immunoreactivity was not con®ned only to the
area of the WGA staining, but occurred also in the more peripheral
cytoplasmic regions (Fig 3c, d).
PC1 and PC2 expression in HDF in situ To further assess the
relevance of the above ®ndings, we performed immunohisto-
chemistry studies of normal adult human skin. As already reported
by Wakamatsu et al (1997), PC1 and PC2 immunostaining was
detected in epidermal keratinocytes as well as in scattered dendritic
cells in the basal layer of the epidermis, whereas omission of the ®rst
antibody did not result in any staining (data not shown). In
addition, PC1 and PC2 staining was also detected in scattered
dermal cells (data not shown). To con®rm the nature of these PC1-
and PC2-positive cells, double immunostaining with an anti-
vimentin antibody and an anti-PC1 or anti-PC2 antibody was
performed. As expected, human epidermal cells were immuno-
reactive for both PC1 and PC2 without apparent difference in the
staining intensity between undifferentiated cells in the basal layer
and differentiated cells in the spinous or granular layer. Immuno-
staining of keratinocytes was con®ned to the cytoplasm and spared
the nuclei. Moreover, both antibodies stained dendritic cells in the
basal layer of the epidermis (Fig 4a, b). By the immunopro®le of
the anti-vimentin antibody, these cells were identi®ed as melano-
cytes and Langerhans cells, which ± in addition to ®broblasts ±
express vimentin (Mahrle et al, 1983). Accordingly, the anti-
vimentin antibody produced prominent immunoreactivity in the
long cytoplasmic processes of dermal cells representing ®broblasts
(Fig 4a±d). In these cells PC1 and PC2 staining was found in
granular structures within the cytoplasm around the nuclei, which
is in accordance with our in vitro ®ndings on the subcellular
distribution of both enzymes. Interestingly, cytoplasmatic PC1 (not
shown) and PC2 immunoreactivity was also observed in dermal
microvascular endothelial cells (Fig 4b, d). In contrast, omission of
either the anti-PC1 or anti-PC2 antibody in the double staining
protocol did not result in any immunostaining, although
immunoreactivity for vimentin of the epidermal dendritic and
dermal cells was indeed maintained (data not shown).
Expression of POMC in HDF in culture As PC1 and PC2 are
the key enzymes regulating POMC processing we checked HDF
for expression of POMC at the RNA and protein level. RT-PCR
of total RNA from HDF revealed an ampli®cation product of the
same size as in NHM (Fig 5). We next examined the expression of
the POMC prohormone by Western immunoblotting using
antibodies directed against a common epitope of both ACTH
and POMC (ACTH18-39). A single band of approximately 33 kDa
could be detected that comigrated exactly with the band in NHM
(Fig 6a). In contrast, whole cell lysates of SK-N-MC cells, a
neuroblastoma-derived cell line that lacks POMC expression
(Verbeeck et al, 1992), did not produce any band. To ascertain
that the detected bands are not biased by uneven protein loading,
the same blot was ®nally stripped and reprobed with an antibody
against a-tubulin (Calbiochem, San Diego, CA). The result
demonstrates that the loaded protein amounts were similar
(Fig 6b).
Expression of the POMC products a-MSH, ACTH, and
b-ED in vesicular structures in cultured HDF It is known
that in neuroendocrine cells POMC peptides are generated and
Figure 2. Protein expression of PC1, PC2, and 7B2 in HDF in
culture. Identical amounts of lysate proteins (30 mg per lane) from HDF
and NHM (positive control) were separated by NuPAGE (4%±12%
gradient) and immunoblotted with antibodies against PC1, PC2, and
7B2. (a) The anti-PC1 antibody (1:500) detected a double band of 84
and 72 kDa in HDF related to the low active and very active isoforms of
PC1. The lower band comigrated with the 72 kDa band in NHM.
Proteins of approximately 46 kDa in HDF and approximately 51 kDa in
NHM are possible degradation products of PC1. (b) A protein of 66 kDa
was detected after immunoblotting with anti-PC2 antibodies (1:500) in
both HDF and NHM. (c) Western immunoblotting with anti-7B2
antibodies revealed a single protein of approximately 23 kDa in the
range of expected size.
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processed within speci®ed vesicular structures prior to exocytosis
and secretion into the blood stream (Smith and Funder, 1988;
Slominski et al, 2000). We thus investigated the presence of a-
MSH, ACTH, and b-ED by immuno¯uorescence. Confocal laser
scanning microscopy revealed a marked intracellular vesicular
staining for all of these peptides (Fig 7a±c). Immunostaining
occurred throughout the entire cell body but was most accentuated
in vesicular structures around the nuclei. In the majority of the
cells, staining was also observed on the cell membrane. Among the
analyzed POMC peptides, a-MSH and b-ED appeared to be most
prominently expressed (Fig 7a, c). Staining of ®broblasts with
rabbit serum or omission of the primary antibody did not result in
any staining (Fig 7d).
Production and secretion of POMC peptides by HDF
in vitro In order to assess the signi®cance of PC1, PC2, and
Figure 4. PC1 and PC2 antigenicity in situ in
HDF. Deparaf®nized sections were double stained
with antibodies against PC1 (a, c) or PC2 (b, d)
and anti-vimentin (a±d). Bound antibodies were
detected by the immunoperoxidase technique
(PC1 and PC2, red staining) and gold-labeled
secondary antibodies in combination with the
silver enhancement technique (vimentin, black
silver grains). PC1 and PC2 immunostaining was
observed throughout the epidermis (E) and
localized to keratinocytes and scattered dendritic
cells (large arrows) positive for vimentin (small
arrows). PC1 and PC2 immunoreactivity was also
detected in dermal cells (arrowheads), which were
identi®ed as ®broblasts by vimentin immuno-
staining (small arrows). Note PC2 staining of
endothelial cells (small arrowheads). (Double
immunostaining; scale bar: 50 mm.)
Figure 3. Subcellular distribution of PC1 and
PC2 in HDF. Cells were seeded into eight-well
tissue chamber slides, ®xed with methanol and
incubated with anti-PC1 (1:100) and anti-PC2
(1:200) antibodies. Bound antibodies were
detected by a secondary donkey anti-rabbit
antibody conjugated to Texas Red followed by
confocal laser scanning microscopy (red
¯uorescence). (a) PC-1 was expressed mainly in
the perinuclear region in reticular and vesicular
structures that colocalized with the TGN. (c)
PC-2 was localized in the juxtanuclear posed
region and in vesicular structures diffusely
distributed in the peripheral cytoplasm. (b, d)
FITC-labeled WGA was used as a marker for the
TGN (green ¯uorescence). Scale bar: 10 mm.
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7B2 expression in HDF, we examined the production and
secretion of a-MSH, ACTH, and b-ED. As production of some
of these POMC peptides was found to be upregulated by IL-1,
UVB, and PMA in other cutaneous cell types, we wondered if
POMC production and secretion by HDF may also be modulated
by distinct external stimuli (Schauer et al, 1994). Unstimulated cells
as well as cells treated with either IL-1, PMA, or UVA were thus
examined for the amounts of a-MSH, ACTH, and b-ED after
24 h (data not shown) and 48 h. The respective POMC peptides
were determined in both cell lysates and cell supernatants by
radioimmunoassay, immunoradiometric assay, and enzyme
immunoassay in order to quantify the amount of POMC
peptides produced intracellularly as well as the secreted amount.
b-ED and ACTH were constitutively secreted by HDF into the
culture media (b-ED, 217.0 6 11.0 pg per ml; ACTH,
38.2 6 0.6 pg per ml; mean 6 SD) after 48 h. Accordingly,
immunoreactive b-ED and ACTH were found in cell lysates of
unstimulated HDF (b-ED, 122.2 6 6.7 pg per 106 cells; ACTH,
27.0 6 2.3 pg per 106 cells; mean 6 SD). In contrast, a-MSH was
detectable only after 45-fold concentration and appeared to be
secreted by HDF in marginal amounts. Among the different stimuli
(IL-1, PMA, UVA) only IL-1 (10 ng per ml) induced a moderate
but statistically signi®cant increase in the amount of intracellular
a-MSH (9.9 6 0.52 vs 6.4 6 0.46 pg per 106 cells, p < 0001;
mean 6 SD) after 48 h. This IL-1-induced rise in intracellular
a-MSH production was not associated with an elevated secretion
into the supernatant, however.
DISCUSSION
In this study we provide evidence that HDF in vitro and in situ
express the enzymes required for POMC processing, namely PC1
and PC2, as shown by RT-PCR, Western immunoblotting,
immuno¯uorescence, and immunohistochemistry. In addition, we
have demonstrated that POMC as well as the POMC-derived
peptides a-MSH, ACTH, and b-ED are expressed in HDF in vitro.
Figure 6. Detection of the POMC protein in HDF by Western
immunoblotting. Crude lysates (30 mg per lane) from HDF, cultured
NHM (positive control), and SK-N-MC cells (negative control) were
separated by 12% NuPAGE, followed by immunoblotting with (a) an
anti-ACTH antibody (1:10,000) that recognizes both ACTH and
POMC due to a common epitope (ACTH18-39) and (b) an antibody
against a-tubulin.
Figure 5. Detection of POMC-speci®c transcripts by RT-PCR in
HDF. Total RNA was prepared from HDF, reverse transcribed, and
ampli®ed with POMC-speci®c primers followed by 1.5% agarose gel
electrophoresis. A 260 bp size fragment was obtained in both HDF and
NHM (positive control). NC 1, ®rst negative control (substitution of
template with H2O); NC 2, second negative control (substitution of
template with total RNA).
Figure 7. Subcellular distribution of a-MSH,
ACTH, and b-ED in cultured HDF. Cells
were cultured on chamber slides, ®xed with
methanol, and incubated with the primary
antibody against (a) a-MSH (1:50), (b) ACTH
(1:100), or (c) b-ED (1:100). Bound antibodies
were detected with secondary donkey anti-rabbit
antibody conjugated to Texas Red (red
¯uorescence) followed by confocal laser scanning
microscopy. (a±c) Most immunoreactivity was
found in vesicular structures located in the
cytoplasm around the nucleus. (d) Normal rabbit
serum did not produce any speci®c staining. Scale
bar: 20 mm.
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It is well established that several skin cell types including normal
human keratinocytes, microvascular endothelial cells, and malig-
nant and non-malignant melanocytes in vitro produce a-MSH and
ACTH whose levels are upregulated by UV, phorbol ester, or IL-1
(Schauer et al, 1994; Chakraborty et al, 1995, 1996, 1999;
Slominski, 1998, Slominski et al, 1999; Scholzen et al, 2000).
Recently, Teofoli et al (1999) reported on secretion of POMC
peptides by HDF in culture. The same group also detected POMC
transcripts in these cells by northern blotting in an earlier
investigation (Teofoli et al, 1997). With regard to POMC, our
®ndings are in accordance with those of Teofoli et al (1997, 1999)
although the amounts of detectable POMC peptides in the culture
supernatants are much higher than ours. Regardless of these
discrepancies, our studies on PC1 and PC2 expression in HDF
provide compelling evidence that these cells possess the enzymes to
generate POMC peptides.
As shown by our immuno¯uorescence studies most immuno-
reactivity for PC1 was found in the TGN. This is in accordance to
what is known about the compartmentalization of PC1 in cells of
neuroendocrine origin (Vindrola et al, 1992; Benjannet et al, 1993;
Peters et al, 2000). PC1 is synthesized as a 94 kDa proprotein, and
subsequently the N-terminal inhibitory pro-segment is auto-
catalytically removed within the endoplasmatic reticulum. The
resulting low active 84 kDa form of PC1 is further processed by
autocatalytic cleavage of the carboxyl-terminal segment within the
TGN and immature secretory granules. This step ®nally results in
the fully active form of PC1 with a molecular weight of
approximately 66 kDa in the pituitary (Seidah et al, 1999). In
spite of the fact that the low and very active form of PC1 were
detectable on the protein level in HDF by Western immuno-
blotting, however, we could not detect the low active form in
NHM. This is in contrast to the recent ®ndings by Peters et al
(2000) who were able to show expression of both forms in the latter
cell type. Our failure to detect the 84 kDa form in NHM may be
related to differences in the sample preparation as Peters et al (2000)
preferentially used Nonidet P-40 without additional denaturation.
Concerning PC2 it was shown that the 68 kDa active form of PC2
is mainly located in the TGN and in secretory granules of
neuroendocrine cells, where a low pH and increased Ca2+ facilitate
cleavage of the 75 kDa zymogene (pro-PC2) (Vindrola et al, 1992;
Benjannet et al, 1993; Malide et al, 1995; Jutras et al, 1997; Muller
et al, 1997). As demonstrated by our immuno¯uorescence studies,
PC2 in ®broblasts was found in the TGN as well as in vesicular
structures diffusely distributed in the peripheral cytoplasm. In
addition, all POMC products as detected by immuno¯uorescence
were detected in vesicular structures in HDF. As shown by our
immunohistochemistry studies, PC1 and PC2 could also be
detected in HDF in situ. The perinuclear accentuation of PC1
and PC2 immunostaining resembled the subcellular distribution of
these enzymes in vitro. Wakamatsu and coworkers were the ®rst to
detect immunoreactivity for PC1 and PC2 in human epidermal
keratinocytes and melanocytes (Wakamatsu et al, 1997). More
recently, the expression of PC1 and PC2 could also be demon-
strated in murine epidermal keratinocytes and murine sebaceous
units (Mazurkiewicz et al, 2000). None of these authors reported
immunoreactivity of PC1 and PC2 in dermal ®broblasts. This may
be due to the diverse nature of the antibodies used and differences
in epitope unmasking. Immunohistochemical studies on POMC
peptide expression, however, have revealed some immunostaining
for ACTH and a-MSH in isolated dermal cells, whose nature was
not further elucidated (Wakamatsu et al, 1997).
What could be the function of POMC peptides expressed and/
or secreted by HDF? Indeed it still needs to be addressed whether
a-MSH, ACTH, and b-ED are expressed in ®broblasts in situ.
Based on our in vitro studies, b-ED and ACTH are constitutively
secreted in signi®cant amounts without further upregulation by IL-
1, PMA, or UVA irradiation. In contrast to these POMC peptides,
only marginal levels of a-MSH were detected in the culture
supernatants of cultured HDF. None of the examined stimuli
increased their secretion. It remains to be determined if other
stimuli such as TNF-a or histamine, the latter a mast-cell-derived
biogenic amide reported to upregulate POMC synthesis in the
pituitary of male rats, may further increase a-MSH production and
secretion by HDF (Kjaer et al, 1995; Knigge et al, 1995). If POMC
peptides are actually expressed in situ by dermal ®broblasts, they
may modulate the function of their neighboring cells. b-ED may
act on m-opiate receptors, which have been found to be expressed
on human epidermal keratinocytes and in the dermis in adnexal
structures, especially in the ducts of sweat glands and in the
pilosebaceous unit of hair follicles (Bigliardi et al, 1998; Bigliardi-Qi
et al, 2000). With regard to a-MSH, it was shown that a-MSH
in vitro upregulates matrix metalloproteinase 1 at the mRNA level
and increases its enzyme activity in HDF (Kiss et al, 1995). Kiss et al
and our investigative team also observed that a-MSH increases
HDF-derived secretion of IL-8, the latter a repressor of collagen
synthesis (Unemori et al, 1993; BoÈhm et al, 1999b; Kiss et al, 1999).
Recently, we also showed that HDF express the melanocortin-1
receptor and a-MSH reduces collagen I and III deposition in vitro
and mitigates TGF-b-induced ®brosis in vivo (BoÈhm et al,
submitted).2 Thus, a-MSH may act as a modulator of extracellular
matrix composition.
With regard to the possible role of PC1 and PC2, it should also
be noted that other substrates than POMC and ACTH may be
targeted by both enzymes. For example PC1 and PC2 were found
to be involved in endoproteolytic processing of pro-neuropeptide
Y in cultured sympathetic neurons (Paquet et al, 1996). Moreover,
carboxy-terminal conversion of pro®brillin to ®brillin in vitro was
reported to be catalyzed by PC1 and PC2 as well as by other
endoproteases with furin/PACE-like activities (Raghunath et al,
1999). In summary, this study demonstrates the presence of POMC
and POMC peptides as well as crucial components required for the
post-translational processing of POMC into the biologically active
peptides in HDF. By releasing such POMC peptides dermal
®broblasts may have a signi®cant modulatory role in skin
physiology or pathophysiology.
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